Evidence Synthesis

Our services in this area include:

Therapeutic value assessment and optimization are at the very core of all our activities at LASER. The high rate of innovation and competition, along with the increasing pressure on healthcare spending, and the evolution of societal expectations towards health create an impetus for thoroughly exploring and regularly revisiting how to assess the value of health interventions. The industry has already departed from focusing on a simple demonstration of efficacy and safety at the time of approval and has now embarked on the integrated evaluation and optimization of value throughout the product lifecycle, starting at an early stage of development. It is now critical for developers, investors, and health authorities to keep their assessment approaches abreast of the rapid changes in health systems.

In order to support developers’ preparation for HTA and payer appraisals, we have developed a simple and powerful framework, going systematically through the key questions explored by decision makers. This framework can be used to inform drug positioning in the early life of a product and in market access strategy

Through our work with regulatory agencies, HTA organizations, payers, biopharma, medtech companies and investment funds, we have developed and continually improve an array of methods to assess the value of health interventions. This enables us to address the variety of situations and points of view faced by stakeholders of the healthcare systems.

Keep in touch with us

Global Value Dossiers

The Global Value Dossier (GVD) is a pragmatic, single source 3D compendium of information gathered and developed over the life cycle of a product that provides functional access to everything needed to support market access globally. The primary objective of the GVD is successful Reimbursement Submissions.

We use a structured approach to evaluate, synthesize, and translate evidence into a compelling value dossier underpinned by multicriteria decision analysis (MCDA) methodology and HTA gold standards.

  • An integrated system, rooted in the real needs of healthcare decision-makers
  • Systematic, quantitative documentation of healthcare interventions
  • Integration of specific regional information to simplify local submissions

Working as a collaborative team of market access strategists, scientists and experienced reimbursement specialists, we support reimbursement for all your target markets, for an entire region (e.g., Europe), or for a single jurisdiction (e.g., France).

We work to SOPs, tools and templates that ensure consistent style, format, content and quality. Our offices collaborate in:

  • Targeted or systematic literature reviews
  • Needs/gap analyses
  • Data extraction, analysis, synthesis
  • Development of tables, graphs, visuals, etc.
  • Key message and value message development
  • Building the GVD
  • Interactive e-platform development

Multicriteria Decision Analysis (MCDA)

MCDA expertise is available throughout our comprehensive portfolio of services. MCDA has been used for decades in many fields for industrial, technical, social & political priority-setting. It allows consideration of many criteria at once, in combination with the values associated with those criteria.

MCDA-based methods support:

  • Communication: knowledge transfer and dialog among stakeholders
  • Consistency & Continuity: comprehensive lifecycle support
  • Efficiency: reduces duplication
  • Strategy for R&D, product positioning & market access
  • Decisionmaking at all levels (both internal & external) and phases of development

We are pioneers in the development and actualization of pragmatic MCDA for complex healthcare decisionmaking (the EVIDEM framework)

Systematic Literature Review

Systematic review is a commonly used tool in the Market Access and HTA areas of the pharmaceutical industry. The process of conducting a review constitutes identifying, appraising and synthesizing evidence. Through the implementation of systematic reviews and meta-analyses, relevant data are gathered, summarized, and shaped to illustrate and strengthen evidence-based messages. The review is an unbiased and reliable source of information used for decisionmaking purposes.

The principles of systematic review were pioneered at McGill University back in the early 1980′s. Two key members of LASER ANALYTICA, including its founder and chairman Professor Lucien Abenhaim, were active members of that pioneering research team. Building on this legacy, we offer a full array of evidence-building services.

Our services include:

  • Design and implementation of systematic/literature reviews
  • Standard and advanced meta-analyses
  • Mixed and indirect treatment comparisons
  • Meta-regressions
  • Bayesian meta-analyses